XW033MAIntroduction of Emapalumab-lzsg Anti-IFNy Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 10

New Technology›Anatomical Regions›Introduction
  • Billable / Specific Code
ICD-10-PCS XW033MA
CMS Source: FY 2027 ICD-10-PCS dataset. Effective Oct 1, 2026 – Sep 30, 2027.FacebookXLinkedInPrint

XW033MA is a billable ICD-10-PCS procedure code for Introduction of Emapalumab-lzsg Anti-IFNy Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 10. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027). The root operation Introduction involves putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products. In AHRQ's Clinical Classifications Software (CCSR), this procedure falls under Administration of therapeutic substances, NEC.

Code Identity

ICD-10-PCS Code
XW033MA
Billable Status
Yes — Valid for Submission
Code Describes
Introduction of Emapalumab-lzsg Anti-IFNy Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 10
Short Description
Introduce Emapalumab-lzsg in Periph Vein, Perc, New Tech 10
Parent Code
XW0

PCS Table Breakdown

Each ICD-10-PCS code is built from seven characters, each an axis of the procedure. Hover or tap the icons for the official CMS definitions.

PositionDesignationValueMeaning
1SectionXNew Technology
2Body SystemWAnatomical Regions
3Operation0Introduction
4BodyPart3Peripheral Vein
5Approach3Percutaneous
6Device/Substance/TechnologyMEmapalumab-lzsg Anti-IFNy Monoclonal Antibody
7QualifierANew Technology Group 10

In the ICD-10-PCS Alphabetic Index

These FY 2027 ICD-10-PCS Alphabetic Index entries lead to this code:

GAMIFANT(R)
Anatomy or device term that leads here
Iloprost
Leads to this code's table
Sarilumab
Leads to this code's table
Posoleucel
Leads to this code's table
Rezafungin
Leads to this code's table
Treosulfan
Leads to this code's table
Baricitinib
Leads to this code's table
Sabizabulin
Leads to this code's table
Tocilizumab
Leads to this code's table
Caplacizumab
Leads to this code's table
COVID-19 Vaccine
Leads to this code's table
Inebilizumab-cdon
Leads to this code's table
Sulbactam-Durlobactam
Leads to this code's table
CD24Fc Immunomodulator
Leads to this code's table
COVID-19 Vaccine Dose 1
Leads to this code's table

Browse the full ICD-10-PCS Alphabetic Index →

Clinical Classification (CCSR)

AHRQ groups this procedure code into these clinical categories.

ADM021
Administration of therapeutic substances, NEC
Clinical domain: Administration of Therapeutic Substances

Code History

Replaces previously assigned code(s):
  • 3E033GR — Introduce Oth Rx Moncln Ab in Periph Vein, Perc

Similar Procedure Codes

Questions About XW033MA

Is XW033MA a billable code?

Yes. This is a complete seven-character ICD-10-PCS code, specific enough to report Introduction of Emapalumab-lzsg Anti-IFNy Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 10 on inpatient claims from October 1, 2026 through September 30, 2027.

What do the characters in XW033MA mean?

The code breaks down character by character: the 1st character X is the Section (New Technology); the 2nd character W is the Body System (Anatomical Regions); the 3rd character 0 is the Operation (Introduction); the 4th character 3 is the BodyPart (Peripheral Vein); the 5th character 3 is the Approach (Percutaneous); the 6th character M is the Device/Substance/Technology (Emapalumab-lzsg Anti-IFNy Monoclonal Antibody); the 7th character A is the Qualifier (New Technology Group 10).